EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)
ISSN: 2992-4081 ©EEJPH Publications
Volume 5 Issue 2 2024

Advancements in Vaccinology: Developing Next-Generation Vaccines

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The field of vaccinology has revolutionized disease prevention, with vaccines playing a crucial role in reducing and eradicating infectious diseases globally. Traditional vaccines, including live attenuated, inactivated, subunit, and conjugate vaccines, have been instrumental in controlling diseases, but ongoing research focuses on developing next-generation vaccines to address emerging pathogens and improve efficacy. New technologies, such as mRNA and DNA vaccines, coupled with advancements in adjuvants and delivery systems, are redefining the landscape of vaccine development. This paper reviews the evolution of vaccines, current challenges in vaccinology, and emerging trends shaping the future of vaccine design and implementation.

Keywords: Vaccinology, Vaccine development, mRNA vaccines, DNA vaccines, Adjuvants, Live attenuated vaccines.

INTRODUCTION

The development and prevention of various infectious diseases have been greatly influenced by advances in the field of vaccinology. Vaccines are biological preparations used to develop active immunity, causing one's immune system to produce immunological memory against disease parameters. Based on the successful use of vaccines against different infections, a variety of microbial agents have been controlled and eradicated worldwide. Among infectious disease interventions, vaccines have an important role in controlling infectious diseases. Over the years, 13 infections have been controlled internationally using vaccines alone or in combination with other control measures by achieving an 80% reduction in disease incidence. Some diseases have achieved near eradication, and some control is mainly limited to certain geographical regions. The development of vaccines and their launch has remarkably affected the incidence of the number of diseases at global and regional levels [1]. The inclusion of critical reviews in vaccinology and molecular clinical studies in a single journal may help us to understand the mechanisms of vaccines, and in turn, this great progress in understanding the molecular pathogenesis of infectious microbes can result in the development and commercialization of a new generation of vaccines. The editorial in this issue emphasizes the need for clinical applications, as well as the efficacy of advanced vaccines, the role of regulatory authorities in improving vaccine design, and clinical aspects of vaccines such as predictability, safety, economic impact, and placebo-controlled trials. There are several technological advances now that have broadened the vaccinology landscape. Ongoing development in these areas has generated a lot of excitement in the development of a new generation of strategic vaccines. Additionally, the current pandemic has reignited the global zeal and the necessity of the development and clinical testing of suitable vaccines against emerging pathogens [2].

HISTORICAL OVERVIEW OF VACCINES

A historical overview of vaccine development shows the progress made over the years. Variolation and vaccination practices date back to 1000 and 1796 A.D. Notable breakthroughs include Edward Jenner's discovery of using cowpox to prevent smallpox. The field has seen continued improvement and innovation, driven by geographical, economic, social, and moral factors. Major pandemics have prompted vaccinations that saved entire populations. Vaccines for hepatitis B, Haemophilus influenzae type B, and human papillomavirus have made a significant impact. However, challenges such as socio-economic

conditions, research and development struggles, and marketing issues hinder disease control efforts. Vaccines are now widely available for all age groups. They have eliminated or reduced the incidence of many vaccine-preventable diseases. However, there are still challenges like herd immunity, eradicating pathogens, and creating vaccines for chronic diseases. The quest for next-generation vaccines faces infrastructure and resource availability issues [3].

TYPES OF VACCINES

Until now, our understanding of vaccine technologies has been limited to the vaccines that are being implemented for use. However, from a technological standpoint, vaccines are broadly categorized into groups: live attenuated and inactivated, non-replicating subunit vaccines, and conjugate vaccines. The live attenuated vaccines have significant replication potential and high efficacy, whereas the inactivated vaccines are poorly behaving and unsafe. Newer generations of subunit and conjugate vaccines are being developed to strike a balance between immune response and safety profile. A vaccine can now be any combination of these groups that mimics the disease condition to create immunity without causing disease [4]. The majority of vaccines on the market are live attenuated, inactivated, subunit, or conjugate. They have different classifications based on attenuation, mechanism of action, immunogenicity, innate immune response, and background. Live attenuated vaccines elicit strong immune responses and provide long-term immunity. Inactivated vaccines are safe but offer limited immunity. Subunit vaccines are safer than inactivated and more effective than polysaccharides. Conjugate vaccines have a strong immune response and are important for infants and the elderly. Combination vaccines consolidate multiple doses into one regimen and are used for children and adults [5].

LIVE ATTENUATED VACCINES

Live attenuated vaccines use weakened forms of live pathogens to mimic natural infection and drive robust immune responses. They confer long-lasting immunity through various mechanisms and can protect against related and unknown pathogens. Live attenuated vaccines have significantly controlled or eliminated infectious diseases. Examples include measles, mumps, rubella, chickenpox, yellow fever, oral polio, and tuberculosis vaccines. They are used to prevent outbreaks and induce immunity in affected communities. Live vaccines were developed before inactivated vaccines and require special handling and storage. Shipping and storage costs limit their use in developing countries. Large vaccination campaigns have limits in preventing disease spread. Safe, effective, and widely available new vaccines are needed to fully eliminate diseases like measles and tuberculosis. Current live vaccines have limitations among the immunocompromised population and can revert back to a harmful state. Ongoing research aims to enhance the safety and effectiveness of live vaccines [6].

ADJUVANTS AND DELIVERY SYSTEMS

Adjuvants and Delivery Systems in Vaccines There are two major approaches to producing new and more efficacious vaccines against infectious diseases: enhancing antigens with effective adjuvants and delivering antigens in particulate formulations. An adjuvant is an ancillary component of vaccines that serves to enhance the effectiveness of vaccines by several folds. They boost the immune responses of the body to the vaccine's antigens. The mechanism of action behind the addition of an adjuvant to a vaccine plays a critical part in maintaining the quality, lessening the quantity of antigen required, improving the efficacy and duration of immunity, and reducing the emergence of resistance, especially in diseases that require repeated immunization schemes due to waning immunity. The advantages of using adjuvants are enormous. Their primary purpose is to induce inflammation through chronic processes, which results in the recruitment of components of the innate immune system. This would result in improved presentation of antigens to pattern recognition receptors. In general, adjuvants can be classified as: antigen-depot formulations, immune-modulatory formulations, antigen presenting cells' specific stimuli, and non-specific stimulators [7]. Different molecules could be modified to behave as TLRs. Imidazoquinolines and oligodeoxynucleotides have been shown to have vaccine adjuvant activities in animals. The addition of the hapten nitrotyrosine to carrier proteins could produce effective carrier proteins with built-in T-cell help. However, the carriers modified with L-tyrosine or nitrotyrosine caused a six times greater anti-carrier antisera response. The identification of adjuvants that can operate through non-TLR mechanisms has also opened new opportunities in the search for new generation vaccine adjuvants. The adjuvants not only enhance the immune responses induced, but also change the nature of the response to a Th1 or Th2 phenotype, influence the persistence of memory, and potentially reduce the required dose by facilitating a more efficient response [8].

ROLE OF ADJUVANTS IN VACCINE EFFICACY

The choice of adjuvants is crucial in immunization strategies. Adjuvants enhance immune responses and reduce the required antigen amount for vaccination. They can promote Th1 or Th2 cytokine responses and enhance HBsAg protein-specific IgG. Th1 adjuvants are proposed for anti-S-based COVID-19

responses, while a Th2 adjuvant may benefit elderly individuals. Alum is the most widely used adjuvant, with others like incomplete Freund's adjuvant, AS01, AS04, MF59, CpG, and Toll-like receptor ligands showing effectiveness in clinical trials. Although liposomes, saponins, and acylated synthetic nucleotides have preclinical evidence of effectiveness, regulatory barriers hinder their release or licensing [9].

EMERGING TECHNOLOGIES IN VACCINE DEVELOPMENT

Emerging technologies in vaccine development represent the cutting edge of innovations in the field. Some of the most widely discussed advancements include the development of DNA and mRNA vaccines. This type of vaccination has come into prominence as a new platform for vaccines worldwide. DNA vaccines use specific viral antigens to elicit an immune response in the host. Plasmids containing the antigen sequence are currently administered through the intramuscular route using a gene gun or needle-free device. Messenger RNA, on the other hand, encodes the genetic information from the viral antigen that is then synthesized and translated into the antigen. Both vaccination methods have a translational component as they do not use a vector or an adjuvant. Instead, the host's immune system adapts to the antigen directly, precluding the possibility of an antibody response to the delivery vector [10]. DNA and mRNA vaccines develop faster without the actual pathogen. mRNA vaccines were developed within 10-11 months, showing the power of new technologies. Emerging vaccine technologies include virus-like particles, nanoparticle vaccines, vector platforms, and live vector vaccines. However, these innovative vaccines face challenges in affecting the host's physiology. Vaccine development involves assessing dose, enhancers, adjuvants, and reactogenic responses. New vaccine delivery vehicles may bring regulations. More practices and trials are needed for potential vaccines. Pharmaceutical companies drive vaccine development with limited input from regulators. Collaboration is important to protect the public and consider implications. Public perception impacts vaccine acceptance. Educating the public about vaccine development and benefits is crucial [11].

MRNA VACCINES

mRNA vaccines are a new type of vaccines that use the cell's machinery to create specific proteins needed to fight diseases. They have been successfully used for COVID-19 and are now being considered for a pneumonic plague outbreak. Moderna and BioNTech have received licenses for their mRNA vaccines, known as mRNA-1273 and BNT162b2. Moderna's vaccine is conditionally licensed, while BioNTech's is fully licensed. The vaccines have been formulated with an adjuvant to increase stability and effectiveness. Funding and investments have allowed for rapid advancements in research, development, and manufacturing of these vaccines. Both vaccines require two doses and have shown effectiveness against COVID-19, although they may be affected by mutations in the virus. The companies have implemented logistical measures to ensure the vaccines' integrity during transportation. These vaccines demonstrate the potential and benefits of mRNA-based vaccines [12].

CHALLENGES AND FUTURE DIRECTIONS

The road ahead for vaccines and vaccinology is paved with many challenges. Although many nucleotide sequences have been successfully sequenced, numerous vaccines still face the gauntlet of a logistically daunting clinical trial. Clearance through animal studies and their cost estimates, the complexity of scale-up production, and large-scale and sustainable distribution strategies are also necessary. In addition, the financial and social considerations necessary to ensure the effectiveness of any vaccine program are important in assessing the growing commercial and industrial syndromes in terms of service, quality, market structure, and infrastructure. Ultimately, an effort targeting microbes in low-income populations should also ensure that bridging the gap in the application of certain vaccines does not widen the gap in overall healthcare infrastructure or compete with other important vaccines or public health activities. Vaccine culture is a value, rather than a negative benefit, and the assessment of the benefits of introducing a vaccine should also include indirect and unquantified benefits. As with the real world, the situation is further complicated by disparities in financing and access to new vaccines between countries and within the scope of domestic concerns of the governments of lower-income countries. Vaccine developers need to consider the full implementation and delivery of the vaccine from the onset of a licensing application, including planning for new, more sustainable funding sources; promoting ethical procurement; dealing with legal and policy barriers; ensuring state-led health system access, coverage, and the implementation of order; the development of the private sector; and the involvement of non-governmental sectors and the need for a new generation of vaccines suitable for the national recommended secondary maintenance and electoral efforts to address the issue of vaccine length and co-administrational conflict, pre-analysis field studies, and surveillance issues, and enhance the human capacity to manage low- and middle-income populations. Characterized vaccine costs also serve as important barriers to vaccine entry, and newer economical and low-cost vaccine manufacturing technologies should also be considered [13].

CONCLUSION

Vaccines have been instrumental in controlling and eradicating several infectious diseases, and ongoing advancements in vaccinology are set to further revolutionize this field. With the development of next-generation vaccines, including mRNA and DNA-based platforms, there is significant potential to address emerging global health threats and improve vaccine efficacy. However, challenges such as regulatory hurdles, production scalability, and equitable access remain. As vaccinology progresses, collaborative efforts across industries and governments will be essential to overcoming these obstacles and ensuring the widespread availability of safe, effective vaccines that meet the needs of diverse populations.

REFERENCES

1. Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nature reviews Gastroenterology & hepatology. 2020 Sep;17(9):533-42. nature.com
2. Cid R, Bolívar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. Biomolecules. 2021 Jul 21;11(8):1072.
3. Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Human vaccines & immunotherapeutics. 2021 Dec 2;17(12):5255-68.
4. Milgroom MG. Biology of Infectious Disease: From Molecules to Ecosystems. Springer Nature; 2023 Nov 25.
5. KB M, Nayar SA, PV M. Vaccine and vaccination as a part of human life: in view of Covid-19. Biotechnology Journal. 2022 Jan;17(1):2100188.
6. Galen JE, Wahid R, Buskirk AD. Strategies for enhancement of live-attenuated Salmonella-based carrier vaccine immunogenicity. Vaccines. 2021 Feb 17;9(2):162.
7. Correa VA, Portilho AI, De Gaspari E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology. 2022 Oct;167(2):124-38.
8. Santos-Sierra S. Targeting toll-like receptor (TLR) pathways in inflammatory arthritis: two better than one?. Biomolecules. 2021 Aug 30;11(9):1291.
9. Liang Z, Zhu H, Wang X, Jing B, Li Z, Xia X, Sun H, Yang Y, Zhang W, Shi L, Zeng H. Adjuvants for coronavirus vaccines. Frontiers in Immunology. 2020 Nov 6;11:589833.
10. Charlier J, Cicchelero L, Cloherty AP, Hanon E, Hofer M, Goossens F, Arnouts S. From discovery to innovation in animal health: Maturing emerging technologies for industrial development. Biologicals. 2024 Aug 1;87:101783.
11. Karam M, Daoud G. mRNA vaccines: Past, present, future. Asian journal of pharmaceutical sciences. 2022 Jul 1;17(4):491-522.
12. Cavaillon JM, Osuchowski MF. COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. Journal of Intensive Medicine. 2021 Jul 1;1(01):4-13.
13. Zirkle S. EXPERIMENTS AND EXPERIENCES: CURRENT ISSUES IN SCIENCE AND MEDICINE. 2024. jhu.edu

CITE AS: Nyiramana Mukamurera P. (2024). Advancements in Vaccinology: Developing Next-Generation Vaccines. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 5(2):1-4